GWAS Findings Hub

Migration, Crosslink

📖

GWAS Findings Hub

active

wiki page Created: 2026-04-02T07:19:50 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-gwas-findings

📖 Wiki Page

mechanism1302 wordssynced 2026-04-02

GWAS Findings Hub

Genome-Wide Association Studies (GWAS) have identified numerous genetic risk loci for Alzheimer's Disease (AD) and Parkinson's Disease (PD). This hub maps major GWAS hits to biological pathways and therapeutic targets, providing a comprehensive reference for understanding the genetic architecture of neurodegenerative diseases.

Overview

GWAS have revolutionized our understanding of neurodegenerative disease genetics by identifying common variants that contribute to disease risk. Unlike rare pathogenic mutations, GWAS variants typically have modest effect sizes but provide crucial insights into disease biology and therapeutic targets.

Alzheimer's Disease GWAS

Major Risk Loci

...

GWAS Findings Hub

Genome-Wide Association Studies (GWAS) have identified numerous genetic risk loci for Alzheimer's Disease (AD) and Parkinson's Disease (PD). This hub maps major GWAS hits to biological pathways and therapeutic targets, providing a comprehensive reference for understanding the genetic architecture of neurodegenerative diseases.

Overview

GWAS have revolutionized our understanding of neurodegenerative disease genetics by identifying common variants that contribute to disease risk. Unlike rare pathogenic mutations, GWAS variants typically have modest effect sizes but provide crucial insights into disease biology and therapeutic targets.

Alzheimer's Disease GWAS

Major Risk Loci

| Gene | Chromosome | Odds Ratio | Pathway | Primary Mechanism |
|------|------------|------------|---------|-------------------|
| APOE | 19q13.32 | 3.5-4.0 (ε4) | Lipid metabolism, Aβ clearance | Amyloid clearance, neuroinflammation |
| TREM2 | 6p21.1 | 2.9-4.5 | Microglial activation | Phagocytosis, neuroinflammation |
| CLU | 8p21.1 | 1.1-1.2 | Complement system | Aβ clearance, synaptic protection |
| PICALM | 11q14.2 | 1.1-1.2 | Clathrin-mediated endocytosis | Synaptic vesicle trafficking, Aβ production |
| CR1 | 1q32.2 | 1.1-1.2 | Complement system | Aβ clearance, immune modulation |
| BIN1 | 2q14.3 | 1.1-1.2 | Membrane trafficking | Tau pathology, synaptic function |
| ABCA7 | 19p13.3 | 1.1-1.3 | Lipid transport | Aβ processing, phagocytosis |
| CD33 | 19q13.4 | 1.1-1.2 | Sialic acid signaling | Microglial activation, Aβ clearance |
| MS4A cluster | 11q12.2 | 1.1-1.2 | Membrane signaling | TREM2 ligand processing |
| EPHA1 | 7q34 | 1.1-1.2 | Ephrin signaling | Synaptic plasticity, neuroprotection |
| PTK2B | 8p21.1 | 1.1-1.2 | Tyrosine kinase signaling | Synaptic function, excitotoxicity |
| SORL1 | 11q24.1 | 1.2-1.4 | Retromer pathway | APP trafficking, Aβ production |
| PLCG2 | 16q23.1 | 1.1-1.2 | Phospholipase signaling | Microglial activation |
| ABI3 | 17q21.31 | 1.1-1.2 | Actin cytoskeleton | Phagocytosis, cell motility |
| SPI1 | 19q13.4 | 1.1-1.2 | Transcription factor | Microglial differentiation |

AD GWAS Pathway Summary

Mermaid diagram (expand to render)

Key AD GWAS Insights

Amyloid Hypothesis Support: GWAS strongly implicate genes involved in amyloid precursor protein (APP) processing and Aβ clearance (APOE, CLU, SORL1, ABCA7).

Microglial Activation: The TREM2-MS4A-PLCG2 axis reveals microglia as central players in AD pathogenesis.

Lipid Metabolism: APOE and ABCA7 connect lipid homeostasis to neurodegeneration.

Complement System: CR1 and CLU implicate complement-mediated synaptic pruning and Aβ clearance.

Parkinson's Disease GWAS

Major Risk Loci

| Gene | Chromosome | Odds Ratio | Pathway | Primary Mechanism |
|------|------------|------------|---------|-------------------|
| SNCA | 4q21 | 1.3-1.5 | α-synuclein metabolism | Protein aggregation |
| LRRK2 | 12q12 | 1.4-3.0 | Kinase signaling | Protein trafficking, autophagy |
| GBA | 1q21 | 1.4-5.5 | Lysosomal function | Glucocerebrosidase, autophagy |
| PARK16 | 1q32 | 1.1-1.2 | Unknown | Putative ER function |
| GIGYF2 | 11q14 | 1.1-1.2 | Tyrosine kinase signaling | Insulin-like growth factor |
| MAPT | 17q21.31 | 1.2-1.4 | Tau pathology | Microtubule function, tau splicing |
| HLA-DRB1 | 6p21.3 | 1.1-1.3 | Immune response | Antigen presentation, autoimmunity |
| BST1 | 4p15 | 1.1-1.2 | ADP-ribosylation | Inflammatory response |
| RAB7L1 | 2q37 | 1.1-1.2 | Vesicle trafficking | Autophagy, lysosomal function |
| SLC41A1 | 1q32 | 1.1-1.2 | Ion transport | Magnesium homeostasis |
| NUCKS1 | 1q31 | 1.1-1.2 | DNA repair | Transcriptional regulation |
| LAMP3 | 3q27 | 1.1-1.2 | Lysosomal function | Autophagy, MHC II presentation |
| SCAF1 | 19q13 | 1.1-1.2 | SR-related | RNA processing |
| ITPR2 | 12p11 | 1.1-1.2 | Calcium signaling | ER calcium release |
| FAM47E | 4q21 | 1.1-1.2 | Unknown | Putative scaffold protein |

PD GWAS Pathway Summary

Mermaid diagram (expand to render)

Key PD GWAS Insights

Protein Aggregation: SNCA remains the strongest genetic risk factor, directly implicating α-synuclein pathology.

Lysosomal Dysfunction: GBA, LAMP3, and RAB7L1 connect Gaucher disease risk to PD, highlighting the lysosome-autophagy axis.

Immune Modulation: HLA-DRB1 and BST1 suggest immune dysfunction contributes to PD pathogenesis.

LRRK2 Kinase: LRRK2 variants increase risk and are a major therapeutic target with kinase inhibitors in development.

Cross-Disease Genetic Loci

Several genetic loci influence risk for both AD and PD:

Shared Risk Genes

| Gene | AD Effect | PD Effect | Shared Pathway |
|------|-----------|-----------|----------------|
| MAPT | Moderate | Strong | Tau pathology, neurodegeneration |
| HLA region | Moderate | Moderate | Neuroinflammation, immune response |
| GAPD | Moderate | Moderate | Energy metabolism |
| MADD | Moderate | Moderate | Apoptosis, cell death |

Implications for Shared Mechanisms

The overlap between AD and PD genetics suggests:

Neuroinflammation: Both diseases involve microglial activation and immune response genes

Protein Misfolding: While different proteins (Aβ/tau vs α-synuclein), common pathways may underlie aggregation

Cellular Stress: Shared mechanisms in oxidative stress, mitochondrial dysfunction, and ER stress

Therapeutic Implications

AD Therapeutic Targets from GWAS

| Target | Gene | Therapeutic Approach | Status |
|-------|------|----------------------|--------|
| TREM2 agonism | TREM2 | Antibody agonists | Preclinical/Phase 1 |
| APOE modulators | APOE | Gene therapy, small molecules | Research |
| BACE inhibitors | CLU, PICALM | Small molecule inhibitors | Discontinued (toxicity) |
| Microglial modulators | CD33, PLCG2 | Antibody antagonists | Research |
| Retromer stabilizers | SORL1 | Small molecule stabilizers | Phase 2 |

PD Therapeutic Targets from GWAS

| Target | Gene | Therapeutic Approach | Status |
|-------|------|----------------------|--------|
| LRRK2 kinase inhibitors | LRRK2 | Small molecule inhibitors | Phase 1/2 |
| GBA modulators | GBA | Gene therapy, enzyme enhancement | Research |
| α-synuclein aggregation inhibitors | SNCA | Antibody, small molecules | Phase 2/3 |
| Autophagy enhancers | GBA, RAB7L1 | mTOR inhibitors, autophagy modulators | Research |

Methodology Notes

GWAS Discovery Timeline

AD: First large-scale GWAS (2009-2013) identified CLU, PICALM, CR1; subsequent meta-analyses (2013-2022) expanded to 40+ loci
PD: First GWAS (2008-2011) identified SNCA, LRRK2, MAPT; large meta-analyses (2011-2022) identified 90+ loci

Effect Sizes and Significance

Most GWAS variants have odds ratios of 1.1-1.5, reflecting polygenic architecture
APOE ε4 (AD) and GBA variants (PD) are notable exceptions with larger effects
Genome-wide significance threshold: p < 5×10⁻⁸

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

[APOE and Alzheimer's](/genes/apoe)
[TREM2 Therapeutics](/therapeutics/trem2-therapeutics)
[SNCA Variants](/genes/snca)
[LRRK2 Variants](/genes/lrrk2)
[MAPT Protein](/proteins/tau)
[Neuroinflammation in Parkinson's](/mechanisms/neuroinflammation-parkinsons)
[Tau Protein](/proteins/tau)

References

[Kunkle et al., Genetic meta-analysis of AD (2019) (2019)](https://doi.org/10.1038/s41588-019-0358-2)

[Jansen et al., GWAS meta-analysis of AD (2019) (2019)](https://doi.org/10.1038/s41586-019-1675-4)

[Wightman et al., GWAS of AD progression (2021) (2021)](https://doi.org/10.1038/s41588-021-00921-z)

[Nalls et al., Large-scale PD GWAS meta-analysis (2019) (2019)](https://doi.org/10.1016/S1474-4422(19)

[Chang et al., LRRK2 in PD GWAS (2017) (2017)](https://doi.org/10.1093/brain/awx079)

[Liu et al., GBA and PD risk (2017) (2017)](https://doi.org/10.1001/jamaneurol.2016.4887)

[Sims et al., TREM2 variants and AD (2017) (2017)](https://doi.org/10.1056/NEJMoa1612255)

[Holmans et al., PD pathway analysis (2019) (2019)](https://doi.org/10.1093/brain/awz193)

[Desikan et al., Genetic overlap between AD and PD (2017) (2017)](https://doi.org/10.1093/brain/awx139)

[Ferrari et al., Polygenic architecture of neurodegenerative diseases (2022) (2022)](https://doi.org/10.1038/s41582-022-00615-w)

📖 View canonical wiki page →

Related Entities

mechanisms-gwas-findings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-gwas-findings
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-efd5f7597f64
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-gwas-findings'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

54

Outgoing

86

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GWAS Findings Hub

GWAS Findings Hub

Overview

Alzheimer's Disease GWAS

Major Risk Loci

GWAS Findings Hub

Overview

Alzheimer's Disease GWAS

Major Risk Loci

AD GWAS Pathway Summary

Key AD GWAS Insights

Parkinson's Disease GWAS

Major Risk Loci

PD GWAS Pathway Summary

Key PD GWAS Insights

Cross-Disease Genetic Loci

Shared Risk Genes

Implications for Shared Mechanisms

Therapeutic Implications

AD Therapeutic Targets from GWAS

PD Therapeutic Targets from GWAS

Methodology Notes

GWAS Discovery Timeline

Effect Sizes and Significance

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

GWAS Findings Hub

GWAS Findings Hub

Overview

Alzheimer's Disease GWAS

Major Risk Loci

GWAS Findings Hub

Overview

Alzheimer's Disease GWAS

Major Risk Loci

AD GWAS Pathway Summary

Key AD GWAS Insights

Parkinson's Disease GWAS

Major Risk Loci

PD GWAS Pathway Summary

Key PD GWAS Insights

Cross-Disease Genetic Loci

Shared Risk Genes

Implications for Shared Mechanisms

Therapeutic Implications

AD Therapeutic Targets from GWAS

PD Therapeutic Targets from GWAS

Methodology Notes

GWAS Discovery Timeline

Effect Sizes and Significance

See Also

External Links

Related Pages

References

💬 Discussion